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Summary
Puumala hantavirus (PUUV) infection causes nephropathia epidemica (NE), a relatively mild form of haemorrhagic fever with 
renal syndrome (HFRS). Hypophyseal haemorrhage and hypopituitarism have been described in case reports on patients 
with acute NE. Chronic hypopituitarism diagnosed months or years after the acute illness has also been reported, without 
any signs of a haemorrhagic aetiology. The mechanisms leading to the late-onset hormonal defects remain unknown. Here, 
we present a case of NE-associated autoimmune polyendocrinopathy and hypopituitarism presumably due to autoimmune 
hypophysitis. Thyroid peroxidase antibody seroconversion occurred between 6 and 12 months, and ovarian as well as 
glutamate decarboxylase antibodies were found 18 months after acute NE. Brain MRI revealed an atrophic adenohypophysis 
with a heterogeneous, low signal intensity compatible with a sequela of hypophysitis. The patient developed central (or 
mixed central and peripheral) hypothyroidism, hypogonadism and diabetes insipidus, all requiring hormonal replacement 
therapy. This case report suggests that late-onset hormonal defects after PUUV infection may develop by an autoimmune 
mechanism. This hypothesis needs to be confirmed by prospective studies with sufficient numbers of patients.
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Learning points:
• Pituitary haemorrhage resulting in hypopituitarism has been reported during acute HFRS caused by PUUV and other
hantaviruses.
• Central and peripheral hormone deficiencies developing months or years after HFRS have also been found, with
an incidence higher than that in the general population. The pathogenesis of these late-onset hormonal defects
remains unknown.
• This case report suggests that the late-onset hypopituitarism and peripheral endocrine defects after HFRS could
evolve via autoimmune mechanisms.
• The sensitivity of current anti-pituitary antibody (APA) tests is low. A characteristic clinical course, together
with typical brain MRI and endocrine findings may be sufficient for a non-invasive diagnosis of autoimmune
hypophysitis, despite negative APAs.
Background
Hantaviruses cause haemorrhagic fever with 
renal syndrome (HFRS) in Eurasia and hantavirus 
cardiopulmonary syndrome (HCPS) in the Americas (1). 
Puumala hantavirus (PUUV) causes a mild HFRS called 
nephropathia epidemica (NE). In Finland, annually 
1000–3000 cases of NE are serologically diagnosed. The 
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typical features of NE are increased capillary permeability, 
renal involvement and thrombocytopenia, the latter 
rarely causing serious haemorrhages (1). The patients 
commonly suffer from high fever, headache, reduced 
visual acuity, abdominal pain, nausea and backache (1).
Hypophyseal haemorrhage and panhypopituitarism 
have been described in case reports on patients with 
NE (2, 3, 4, 5, 6, 7, 8). Defects of the gonadal and/or 
thyroid axis have been found in more than half of the 
patients during the acute phase of NE (9). We have also 
reported chronic hypopituitarism in 5 of 54 patients, 
primary hypothyroidism in 5 patients and chronic 
subclinical testicular failure in 5 of 37 men during 
a median follow-up of 5  years after NE (9). Chronic 
hypopituitarism was also identified in 18% of patients 
with a previous HFRS in a retrospective Serbian study 
of 60 adults who had recovered from HFRS years ago 
(10). Thus, patients with HFRS may be at high risk of 
developing hypopituitarism or peripheral hormone 
deficiencies later on (8, 9, 10). However, no obvious 
late-onset hypopituitarism was diagnosed in a cohort of 
47 patients re-examined 4–8 years after NE in Northern 
Finland (11). The pathophysiological mechanisms of 
hypopituitarism developing as a late complication of NE 
remain unclear.
We present a patient who developed an autoimmune 
polyendocrine syndrome and hypopituitarism possibly 
due to autoimmune hypophysitis six to twelve months 
after the acute NE. We also review previous case reports on 
HFRS-induced hypopituitarism.
Table 1 Basic laboratory test results during acute nephropathia epidemica and at the 1-month follow-up visit.
Parameter
Lowest level at 
hospital
Highest level at 
hospital At discharge At 1-month follow-up Reference range
WBC (109/L) 5.5 45 5.8 6.8 3.4–8.2
Platelet count (109/L) 5 207 207 260 150–360
Haemoglobin (g/L) 90 202 97 114 117–155
CRP (mg/L) 8.7 57.4 8.7 <1 0–10
ALT (U/L) 13 35 13 N/A 10–45
Creatinine (µmol/L) 206 891 206 89 50–90
Urea (mmol/L) 12.9 35.2 12.9 N/A 2.6–6.4
Potassium (mmol/L) 3.7 5.1 3.9 N/A 3.3–4.8
Sodium (mmol/L) 121 132 130 N/A 137–144
ALT, alanine transaminase; CRP, C-reactive protein; N/A, not assessed; WBC, white blood cells.
Table 2 Summary of the hormonal test results during acute NE and at the follow-up visits.
Variables (units) Acute NE 1-month follow-up 6-month follow-up 12-month follow-up
24-month 
follow-up Reference range
fT4 (pmol/L) 10.7 7.7 7.8 18.11 16.71 11.0–22.0
TSH (mU/L) 9.1 0.64 4.1 <0.011 0.251 0.27–4.2
Oestradiol 
(nmol/L)
1.09 0.04 <0.02 0.172 0.172 *
FSH (U/L) 3.0 2.8 4.1 1.52 1.72 *
LH (U/L) 12.2 0.9 1.5 0.82 1.52 *
GH (mU/L) 59.4 0.5 0.5 0.3 0.33 0.0–11.0
IGF-1 (nmol/L) 13 17 12 16 9** 12–46
10–37**
Cortisol (nmol/L) 1284 277 356 253 249** 180–680
170–500**
ACTH (ng/L) 12 11 19 20 10 0.0–46.0
PRL (mU/L) 439 366 256 283 240 102–496
TPOAb (kU/L) <5 13 23 85 66 <34
1On levothyroxine substitution, 2on oestrogen–progesterone substitution, *oestradiol, FSH and LH values were evaluated according to the phase of the 
menstrual cycle, **IGF-1 and cortisol laboratory test methods changed during the follow-up. The new reference ranges and the values measured with 
the new methods are marked with asterisks (**).
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Case presentation
A 25-year-old previously healthy woman presented 
with fever of 39°C, oliguria and lower back pain. At 
presentation, the plasma C-reactive protein (CRP) 
concentration was 39 mg/L and urinalysis revealed 
proteinuria (+++) and haematuria (++). Pyelonephritis 
was suspected, and she was admitted to a ward in the 
primary health care centre. Intravenous cefuroxime 
was started. The patient began to suffer from nausea, 
vomiting, and visual disturbances, and she was 
transferred to Tampere University Hospital. NE was 
suspected, and a point-of-care anti-PUUV antibody test 
(Reascan Puumala IgM, Reagena International, Toivala, 
Finland) was returned positive. The patient was anuric 
and hypotensive, and i.v. fluids were administered. 
During the next few days, she experienced headache and 
dizziness. Diuresis restarted on day six after the onset 
of fever. The highest daily urinary output was 3700 mL 
in the polyuric phase. The mild headache was cured by 
paracetamol and the visual disturbances soon subsided. 
The patient was discharged 14 days after admission.
Investigations
The diagnosis of NE was verified by high levels of 
specific anti-PUUV IgM and IgG antibodies. Other 
laboratory findings (Table 1) typical of NE included severe 
thrombocytopenia, leukocytosis and elevated plasma 
creatinine and urea concentrations, as well as proteinuria 
and haematuria. On the first few days of hospitalisation, 
serum levels of cortisol and growth hormone (GH) were 
high, and free thyroxine (fT4) was low (Table 2).
Outcome and follow-up
The patient participated in a prospective study of the 
hormonal consequences of NE, and written informed 
consent was obtained. At the first follow-up visit one 
month after the acute illness, the patient was slightly 
anaemic, but other laboratory findings were normal 
(Table 1). She still had fatigue and an irregular menstrual 
cycle. Three months after the NE, the patient started to 
suffer from hot flushes, mild headache, sleeping disorders, 
oedema and amenorrhea. Six months after the acute 
illness, central hypothyroidism and hypogonadotrophic 
hypogonadism were detected (Table  2). There were 
no symptoms or laboratory findings compatible with 
diabetes insipidus (DI). Levothyroxine and oestrogen–
progesterone replacement therapy were started.
Brain magnetic resonance imaging (MRI, 3 Tesla) was 
performed 9 months after the acute NE and showed an 
atrophic adenohypophysis with a heterogeneous, low 
signal intensity, compatible with a sequela of hypophysitis 
(Fig. 1). There were no signs of haemorrhage, tumours or 
other abnormal findings on the MRI scan.
At the 12-month follow-up visit, the patient reported 
constipation, abnormal thirst, polyuria and loss of 
appetite. The laboratory tests showed high plasma 
sodium level (145  mmol/L). DI was suspected, and a 
therapeutic trial with desmopressin p.o. was commenced. 
Desmopressin substitution (60 µg b.i.d.) corrected the 
polyuria and other symptoms and normalised the plasma 
sodium concentration.
Plasma thyroid peroxidase antibody (TPOAb) levels 
were normal during acute NE and at one-month and six-
month follow-up visits, but increased by the 12-month 
follow-up visit (Table 2). Due to the clinical signs of DI 
Figure 1
Brain MRI scan (T1-weighted) 9 months after the acute NE, showing an 
atrophic adenohypophysis (arrow) with a heterogeneous, low signal 
intensity, compatible with a sequela of hypophysitis. (A) Coronal plane. 
The height of the hypophysis is 2 mm. (B) Sagittal plane. The patient 
developed diabetes insipidus later on, but at this point, the ‘bright spot’ 
is still visible in the posterior pituitary.
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Table 3 Summary of previous case reports on HRFS-related panhypopituitarism.
Study
 
 
 
Type of hormonal deficiency
Time from HFRS to 
hypopituitarism
Radiological or 
histological 
findings 
(imaging 
modality)
Follow-up 
time
Hormonal 
recoveryACTH TSH LH/FSH GH* AVP
Forslund et al. 
(2)
x x x N/A – 15 years Empty sella (CT) N/A No
Settergren 
et al. (5)
x x x xa,c – 6 mo – N/A No
Suh et al. (14) x x x xc N/A 3 mo Haemorrhage, 
later atrophy 
(MRI)
3 mo No
Park and Pyo 
(15)
x x x xc N/A Acute – N/A N/A
Kim et al. (16) x x N/A xc N/A 13 years – 1 mo No
Hautala et al. 
(3)
x x x N/A N/A 5 mo Acute: Enlarged 
pituitary 
gland, 
haemorrhage
10 mo No
10 mo: 
Decreased 
pituitary 
gland size and 
partial 
resorption of 
haemorrhage 
(MRI)
x x x – N/A Acute Acute: Enlarged 
pituitary 
gland, 
haemorrhage
2 mo No
2 mo: 
Decreased 
pituitary 
gland size and 
partial 
resorption of 
haemorrhage 
(MRI)
Sane and 
Färkkilä (4)
x x x xb – 10 mo Decreased 
pituitary 
enhancement 
(CT)
17 mo No
Pekic et al. (8) x x x xa,b,c N/A 1.5 years Atrophy, empty 
sella (MRI)
N/A No
x x x xa,b,c N/A 2 years 1 mo No?
x x x xb N/A 2 years 15 days No?
Jost et al. (6) x x x N/A N/A Acute Acute: Enlarged 
pituitary 
gland 
5 mo Partial**
5 mo: Normal 
(MRI)
Sarigüzel et al. 
(17)
x x x xb – Acute Haemorrhage, 
atrophy (MRI)
16 mo No
Kaybas et al. 
(18)
x N/A x – N/A Acute Normal (MRI) N/A N/A
ACTH, adrenocorticotropic hormone; AVP, arginine vasopressin; d, days; FSH, follicle-stimulating hormone; GH, growth hormone; LH, luteinizing 
hormone; mo, months; N/A, data not available; TSH, thyroid-stimulating hormone; y, years.
*GH/IGF-1 axis deficiency was diagnosed by determining aserum GH level, or bserum IGF-1 level or by conducting a cGH axis stimulation test.
**Adrenocortical and thyroid axis recovered, and gonadal axis did not.
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and brain MRI findings, hypophysitis was suspected and 
further etiological investigations were scheduled. Serum 
calcium, angiotensin-converting enzyme, lysozyme, 
antinuclear antibody (ANA) and IgG4 levels were normal. 
Anti-pituitary antibodies (APA) were measured by a line blot 
and a radioimmuno-precipitation assay (MVZ Laboratory 
Dr Volkmann and Colleagues, Karlsruhe, Germany), and 
the tests yielded normal results. Glutamate decarboxylase 
antibody (GADAb 892.7 IU/mL, reference <10 IU/mL), 
TPOAb (53 kU/L, reference <34 kU/L) and ovarian antibody 
(OvarAb titer 10, reference <1) tests were all positive. The 
anti-adrenal antibody (AdrAb) titre was normal (<1). The 
GADAbs were measured by an enzyme immunoassay 
(Euroimmune anti-GAD-ELISA, Luebeck, Germany), 
whereas the OvarAbs and the AdrAbs were measured by 
indirect immunofluorescence (PhD 1xSystem, Bio-Rad 
Laboratories) on sections of primate ovary and adrenal 
gland respectively, at the certified Huslab Laboratories, 
Helsinki, Finland. Other measurements were performed 
by the routine laboratory methods of the certified Fimlab 
Laboratories, Tampere, Finland.
At the latest visit, 2  years after NE, the patient 
was asymptomatic on desmopressin, l-thyroxine and 
oestrogen–progesterone substitution. Despite the 
oestrogen substitution, the IGF-1 level was borderline low 
and cortisol was in the low normal range (Table 2). The 
follow-up is continued at the Endocrinology Outpatient 
Clinic.
Discussion
To our knowledge, this is the first case reported with 
autoimmune polyendocrinopathy and hypopituitarism 
developing soon after acute NE. Our patient started to 
suffer from symptoms suggestive of hormonal deficiencies 
three months after the NE. Laboratory tests revealed 
hypopituitarism six months after the discharge from 
hospital. Partial DI was diagnosed one year after NE. Nine 
months after the NE, brain MRI showed atrophy of the 
adenohypophysis with a heterogeneous, low signal intensity, 
compatible with a sequela of hypophysitis. Autoantibodies 
emerged during the first 18 months after the NE. The APAs 
were negative, but the diagnostic sensitivity and specificity 
of APA tests are known to be low (12, 13).
Previously, only one case report has been published on 
NE-associated hypophysitis (6). The patient had transient 
panhypopituitarism, requiring hormonal replacement 
therapy with l-thyroxine and hydrocortisone during 
the acute NE. In contrast with the present case, the 
hormone levels soon normalised with the resolution of 
the acute PUUV infection and remained normal during 
the follow-up of 5  months. In that case report, brain 
MRI showed enlargement of the pituitary gland, but no 
pituitary haemorrhage or necrosis and no hypothalamic 
alterations (6). Both the clinical course and the radiological 
characteristics of the previous case suggest a direct effect 
of the viral infection, rather than an autoimmune 
mechanism, causing the transient pituitary defect.
Table  3 summarises eleven previous case reports (2, 
3, 4, 5, 6, 8, 14, 15, 16, 17, 18) with 14 well-characterised 
cases of HFRS-related panhypopituitarism. Five patients 
were diagnosed with hypopituitarism requiring chronic 
hormonal replacement, starting from the acute phase of 
HFRS (3, 6, 15, 17, 18). Nine patients developed late-onset 
panhypopituitarism months or years after HFRS (2, 3, 4, 
5, 8, 14, 16). A lethal case of hypophyseal haemorrhage 
during acute NE was also reported (3). In addition to 
the cases of panhypopituitarism represented in Table  3, 
we found five cases of chronic hypogonadotrophic 
hypogonadism, two with central hypothyroidism and 
three isolated ones, in the previous retrospective analysis 
of 54 NE patients (9). In the retrospective series of 60 
patients with previous HFRS, there were six cases of a 
single pituitary hormone deficit and five cases of multiple 
pituitary hormone deficiencies respectively (10).
The pathophysiology of chronic hormone deficiencies 
after HFRS is still unclear. Viral infections have been linked 
to the pathogenesis of several autoimmune diseases. For 
example, many viruses such as enteroviruses have been 
associated with type 1 diabetes (19). It is possible that 
an acute PUUV infection may affect the pituitary and 
peripheral endocrine glands, as well as the immune system, 
enhancing the production of autoantibodies against the 
endocrine organs. In our patient, TPO seroconversion 
appeared between 6 and 12 months after NE. Measured 
18 months after HFRS, TPO, ovarian and GAD antibody 
tests were all positive.
Several lines of evidence suggest that primary 
hypophysitis may develop by an autoimmune mechanism 
(12, 20). Pregnancy and childbirth are known risk factors 
for hypophysitis. Lymphocytic hypophysitis is commonly 
associated with autoimmune diseases, such as Hashimoto’s 
thyroiditis, Graves’ disease, Addison’s disease, type 1 
diabetes, atrophic gastritis and Sjögren’s syndrome. Such 
an association has been reported in 25–50% of the cases 
(12, 20).
Hypopituitarism is the most common presentation of 
autoimmune hypophysitis. The typical order of trophic 
hormone deficiency has been reported as ACTH > TSH > FSH/
LH > PRL > GH (12). However, the recent report with 76 cases 
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from Germany found hypogonadotrophic hypogonadism, 
the most frequent hormonal defect in primary 
hypophysitis (13). Our patient first started to experience 
symptoms suggestive of hypogonadism, three months 
after NE. Central hypothyroidism and hypogonadotrophic 
hypogonadism were diagnosed six months after the acute 
NE, and hormonal substitutions were started. Her cortisol 
levels have been in the low normal range, which is likely 
to reflect an impaired cortisol production, in view of the 
oestrogen replacement therapy increasing the cortisol-
binding globulin concentration.
At the acute phase of hypophysitis, a sellar mass effect 
may develop, provoking headache, diplopia and visual 
field deficits. Infundibular or posterior pituitary defects 
may cause antidiuretic hormone (ADH and vasopressin) 
deficiency and central DI, presenting with polyuria and 
polydipsia in 20–48% of patients with autoimmune 
hypophysitis (12). In most cases of hypophysitis, the level of 
PRL is normal or even low (21), as in our patient. During the 
anuric phase of acute NE, the patient had hyponatraemia. 
Fluid retention associated with acute kidney injury was 
probably an important cause of low sodium concentration 
at that time. Nevertheless, hyponatraemia might also be 
caused by excessive secretion of ADH, i.e. an acute SIADH. 
The partial DI of the patient, diagnosed one year after NE, 
reflected a slight defect of the hypothalamic-infundibulo-
neurohypophyseal system, as the intense signal of the 
posterior pituitary was still visible on MRI, and there 
was no visible pathology in the infundibulum or the 
hypothalamus, 3 months before the diagnosis of DI.
The brain MRI of our patient revealed an atrophic 
adenohypophysis with a heterogeneous, low signal 
intensity nine months after acute NE. These findings 
are compatible with a sequela of hypophysitis 
(12). Haemorrhage may also cause atrophy of the 
adenohypophysis (13). However, our patient presented no 
symptoms or clinical findings indicative of hypophyseal 
haemorrhage either during acute NE or during the 
follow-up. A definitive diagnosis of hypophysitis requires 
histological verification from a biopsy specimen, but a 
characteristic clinical course, together with typical MRI 
and hormonal findings have been suggested to suffice for 
a non-invasive diagnosis (12, 13). Distinctive radiological 
features in acute autoimmune hypophysitis are symmetric 
enlargement of the pituitary gland, homogenous post-
gadolinium enhancement, thickened infundibulum in 
the midline, loss of posterior ‘bright spot’ on T1 imaging 
and intact sellar floor (12, 22). A central hypointensity, 
representing necrosis or cyst formation, has been reported 
in up to one-third of the patients (13, 21). At later stages 
of hypophysitis, pituitary atrophy and empty sella are 
typical findings on MRI (12).
Circulating anti-pituitary autoantibodies (APA) may be 
detected in autoimmune processes of the pituitary gland. 
The low diagnostic sensitivity and specificity of present APA 
tests unfortunately limit their diagnostic utility (12, 20). 
The present patient was negative for APAs, but the clinical 
picture and the presence of several other autoantibodies 
make autoimmune hypophysitis a plausible cause of her 
hypopituitarism. A direct effect of the PUUV infection, 
increased capillary permeability or a minor haemorrhagic 
damage are other possible mechanisms that may have led 
to the pituitary atrophy and panhypopituitarism observed.
In conclusion, we report the first case of NE-associated 
autoimmune polyendocrinopathy and a possible 
autoimmune hypophysitis. An autoimmune mechanism 
could explain the late-onset hypopituitarism that has 
been reported to develop months or years after HFRS (8, 
9, 10). Autoimmune inflammation could also explain 
the insufficiencies of peripheral hormonal glands, which 
seem to be more frequent after NE than in the general 
population (9). The case reports and retrospective cohorts 
published so far call for prospective studies, to clarify 
the epidemiology and the mechanisms of hormonal 
deficiencies after NE and other types of HFRS.
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